Accès gratuit
Numéro
Med Sci (Paris)
Volume 26, Numéro 4, Avril 2010
Page(s) 371 - 376
Section M/S revues
DOI https://doi.org/10.1051/medsci/2010264371
Publié en ligne 15 avril 2010
  1. Pinter JD, Eliez S, Schmitt JE, et al. Neuroanatomy of Down’s syndrome: a high-resolution MRI study. Am J Psychiatry 2001; 158 : 1659–65.
  2. Mann DM, Royston MC, Ravindra CR. Some morphometric observations on the brains of patients with Down’s syndrome: their relationship to age and dementia. J Neurol Sci 1990; 99 : 153–64.
  3. Delabar JM, Theophile D, Rahmani Z, et al. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet 1993; 1 : 114–24.
  4. Ronan A, Fagan K, Christie L, et al. Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region. Med Genet 2007; 44 : 448–51.
  5. Aït Yahya-Graison E, Aubert J, Dauphinot L, et al. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am J Hum Genet 2007; 81 : 475–91.
  6. Kleschevnikov AM, Belichenko PV, Villar AJ, et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 2004; 24 : 8153–60.
  7. Shinohara T, Tomizuka K, Miyabara S, et al. Mice containing a human chromosome 21 model behavioral impairment and cardiac anomalies of Down’s syndrome. Hum Mol Genet 2001; 10 : 1163–75.
  8. O’Doherty A, Ruf S, Mulligan C, et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005; 309 : 2033–7.
  9. Ortiz-Abalia J, Sahún I, Altafaj X, et al. Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. Am J Hum Genet 2008; 83 : 479–88.
  10. Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006; 281 : 4292–9.
  11. Roper RJ, VanHorn JF, Cain CC, Reeves RH. A neural crest deficit in Down syndrome mice is associated with deficient mitotic response to Sonic hedgehog. Mech Dev 2009; 126 : 212–9.
  12. Clark S, Schwalbe J, Stasko MR, et al. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp Neurol 2006; 200 : 256–61.
  13. Fernandez F, Morishita W, Zuniga E, et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007; 10 : 411–3.
  14. Rueda N, Flórez J, Martínez-Cué C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 2008; 433 : 22–7.
  15. Salehi A, Faizi M, Colas D, et al. Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome. Sci Transl Med 2009; 7 : 7–17.
  16. Costa AC, Scott-McKean JJ, Stasko MR. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008; 33 : 1624–32.
  17. Dowjat WK, Adayev T, Kuchna I, et al. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci Lett 2007; 413 : 77–81.
  18. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003; 371 : 199–204.
  19. Guedj F, Sébrié C, Rivals I, et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLOS One 2009; 4 : e4606.
  20. Turleau C, Vekemans M. Trisomie 21 : 50 ans entre médecine et science. Med Sci (Paris) 2010; 26 : 267–72.
  21. Langui D, Lachapelle F, Duyckaerts C. Modèles animaux des maladies neurodégénératives. Med Sci (Paris) 2007; 23 : 180–6.
  22. Clavaguera F, Goedert M, Tolnay M. Induction et propagation de la pathologie par la protéine tau chez un modèle murin de la maladie d’Alzheimer. Med Sci (Paris) 2010; 26 : 121–5.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.